Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study

NCT00424268 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00424268
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00424268 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Roflumilast in COPD Patients Treated With Tiotropium. A 24-week, Double-blind Study With 500 µg Roflumilast Once Daily Versus Placebo. The HELIOS Study
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
July 31, 2008
Enrollment
743 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease